Nyxoah named Liam Kelly its new chief executive officer, effective October 1, 2026. Kelly will succeed Olivier Taelman as the medical technology company steps up its U.S. focus following FDA approval and the commercial launch of its Genio device for obstructive sleep apnea.
Kelly has more than 25 years of MedTech experience. He previously served as chairman, president and CEO of Teleflex Incorporated. Nyxoah’s board said his experience scaling commercial operations will help the company drive U.S. adoption of Genio as it enters its next growth phase.